LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

Home・Akcijų sąrašas・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Atidarymo kaina

1.57 4.67

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.5

Max

1.67

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.7M -5.1M
Pardavimai	90K 90K
Pelno marža	-5,701.111
Darbuotojai	25
EBITDA	2.6M -4.9M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+297.35% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2M 44M
Ankstesnė atidarymo kaina	-3.1
Ankstesnė uždarymo kaina	1.57

Actinium Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-14 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025-12-14 23:36; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-12-14 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025-12-14 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025-12-14 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025-12-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025-12-14 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue to Acquire Remaining 64% of Alta Copper

2025-12-14 17:00; UTC

Uždarbis

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025-12-14 08:30; UTC

Įsigijimai, susijungimai, perėmimai

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 07:00; UTC

Įsigijimai, susijungimai, perėmimai

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Akcijų palyginimas

Kainos pokytis

Actinium Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

297.35% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 297.35%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Actinium Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Actinium Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.